Table 1 Disease phase and response to therapy

From: Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis

Patient number Phase and type of relapse at IM therapy Interval ASCT-relapse (months) First-line therapy Initial IM dose Time to achieve CCgR (mos) Time to achieve RT-PCR negativity (months) Follow-up duration (months) Current status
 1 Hem (BC) 14 IM^ 600 3 3 45 RT-PCR negative
 2 Hem (AP) 44 IM 600 3 6 38 RT-PCR negative
 3 Hem (AP) 162 IM 600 3 3 44 RT-PCR negative
 4 Hem (AP) 140 IM 600 6 / 28 RT-PCR positive
 5 Hem (CP) 100 IM 400 3 18 42 RT-PCR negative
 6 Cy 12 IM 400 12 27 36 RT-PCR positive
 7 Cy 116 IM 400 3 12 30 RT-PCR positive
 8 Cy 46 IM 400 6 6 12 RT-PCR negative
 9 Cy 19 IM 400 3 12 24 RT-PCR positive
10 Cy 23 IM 400 3 3 27 RT-PCR negative
11 Cy 51 IM 400 9 18 30 RT-PCR negative
12 Mol 7 IM^ 400 NA 3 21 RT-PCR negative
13 Cy 21 IFNα 400 3 12 18 RT-PCR negative
14 Cy 156 IFNα 400 6 9 36 RT-PCR negative
15 Cy 12 IFNα 400 3 12 44 RT-PCR negative
    3 DLIs      
16 Mol 24 IFNα 600 NA 3 21 RT-PCR negative
    2 DLIs      
  1. Abbreviations: AP=accelerated phase; BC=blast crisis; CP=chronic phase; hem=hematologic; NA=not applicable; RT-PCR=reverse transcription-polymerase chain reaction.
  2. Patients 1–5 received IM whereas in hem relapse: one in BC, three in AP and one in CP. All of them were in complete hematologic response within 1 month of IM therapy. All patients achieved a CCgR in 3–12 months (median 3 months) and a RT-PCR negativity in 3–27 months (median 9 mourns) except for patient no. 4. Currently, 12 patients are in RT-PCR negativity. Patients 1–12 received IM as front-line therapy at relapse. Patients 13–16 received IM after failure of DLI and/or IFNa. Patients no. l and 12 (A) received DL1 during IM therapy, after the achievement of RT-PCR negativity.